切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2025, Vol. 13 ›› Issue (01) : 41 -47. doi: 10.3877/cma.j.issn.2095-5820.2025.01.006

综述

缺氧诱导因子1在消化道肿瘤生长中的研究进展
潘彦孜1, 许健1,()   
  1. 1. 310053 浙江杭州,浙江中医药大学医学技术与信息工程学院
  • 收稿日期:2024-04-29 出版日期:2025-02-28
  • 通信作者: 许健
  • 基金资助:
    浙江省医药卫生科技计划项目(2024XY064)浙江省中医药科技计划项目(2023ZL056)

Hypoxia-inducible factor 1: A pivotal regulator in digestive tract tumor progression and therapeutic targeting

Yanzi Pan1, Jian Xu1,()   

  1. 1. School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou Zhejiang 310053, China
  • Received:2024-04-29 Published:2025-02-28
  • Corresponding author: Jian Xu
引用本文:

潘彦孜, 许健. 缺氧诱导因子1在消化道肿瘤生长中的研究进展[J/OL]. 中华临床实验室管理电子杂志, 2025, 13(01): 41-47.

Yanzi Pan, Jian Xu. Hypoxia-inducible factor 1: A pivotal regulator in digestive tract tumor progression and therapeutic targeting[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2025, 13(01): 41-47.

消化道肿瘤是一组与消化系统及其附属器官相关的肿瘤,严重危害着人类的健康与安全。缺氧诱导因子1(HIF-1)是一种随着细胞内氧浓度变化而调节基因表达的转录激活因子,其表达随细胞内氧浓度变化而调节,并通过激活基因转录在肿瘤细胞对缺氧的适应中发挥关键作用,这些基因转录调节多种生物过程,包括葡萄糖代谢和侵袭转移,因此HIF-1成为有吸引力的消化道肿瘤治疗靶点。本文开展了HIF-1在消化道肿瘤生长进程中分别对细胞糖代谢、肿瘤转移和靶向治疗产生影响的综述。

Digestive tract malignancies, a heterogeneous group of tumors affecting the gastrointestinal system and associated organs, pose significant threats to global health. Hypoxia-inducible factor 1 (HIF-1), an oxygen-sensitive transcriptional activator, dynamically regulates gene expression in response to intracellular oxygen fluctuations. This master regulator drives tumor cell adaptation to hypoxic microenvironments through transcriptional control of critical biological processes, including glycolytic reprogramming and metastatic progression, thereby establishing HIF-1 as an attractive target for gastrointestinal cancer treatment. This article provides a review of the effects of HIF-1 on cellular glucose metabolism, tumor metastasis, and targeted therapy in digestive tract tumor igenesis.

1
XING P, ZHONG Y, CUI X, et al. Natural products in digestive tract tumors metabolism: Functional and application prospects[J].Pharmacological research, 2023, 191: 106766.
2
AHMAD A, TIWARI R K, SIDDIQUI S, et al. Emerging trends in gastrointestinal cancers: Targeting developmental pathways in carcinogenesis and tumor progression[J]. International review of cell and molecular biology, 2024, 385: 41-99.
3
RAKOTOMALALA A, ESCANDE A, FURLAN A, et al. Hypoxia in solid tumors: How low oxygenation impacts the "Six Rs" of radiotherapy[J]. Frontiers in endocrinology, 2021, 12: 742215.
4
陈影, 庄蕾, 张丹红, 等. 低氧微环境通过TGFBI调控Wnt/β-catenin通路介导胰腺癌化疗耐药及机制研究[J]. 现代肿瘤医学, 2024,32(1): 42-46.
5
KUBAICHUK K, KIETZMANN T. USP10 contributes to colon carcinogenesis via mTOR/S6K mediated HIF-1α but not HIF-2α protein synthesis[J]. Cells, 2023, 12(12): 1585.
6
赵斌燕, 齐峰. 关于缺氧对细胞及消化道系统影响的研究[J]. 高原医学杂志, 2005, 15(4): 61-64.
7
YFANTIS A, MYLONIS I, CHACHAMI G, et al. Transcriptional response to hypoxia: The role of HIF-1-associated co-regulators[J].Cells, 2023, 12(5): 798.
8
VANDERHAEGHEN T, BEYAERT R, LIBERT C. Bidirectional crosstalk between hypoxia inducible factors and glucocorticoid signalling in health and disease[J]. Frontiers in immunology, 2021, 12:684085.
9
邢英琦, 徐静, 李琳, 等. 缺氧诱导因子(HIF-1)的结构调节与靶基因研究进展[J]. 中国实验诊断学, 2011, 15(1): 177-179.
10
HE F, XIAO H, CAI Y, et al. ATF5 and HIF1α cooperatively activate HIF1 signaling pathway in esophageal cancer[J]. Cell communication and signaling, 2021, 19(1): 53.
11
DONG S, LIANG S, CHENG Z, et al. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer[J]. Journal of experimental & clinical cancer research, 2022, 41(1): 15.
12
LUO Z, TIAN M, YANG G, et al. Hypoxia signaling in human health and diseases: Implications and prospects for therapeutics[J]. Signal transduction and targeted therapy, 2022, 7(1): 218.
13
石松长, 黄昌明. PI-3K[MS1]/Akt信号通路与消化道肿瘤的研究进展[J]. 医学综述, 2007(14): 1070-1072.
14
杨梦思, 周娜, 王志钢, 等. 转录因子HIF-1α及其信号通路在疾病发生中的作用研究进展[J].生物技术通报, 2016, 32(8): 8-13.
15
LIU S, KANG L, SONG Y, et al. Role of the HIF-1α/BNIP3 signaling pathway in recurrent hepatocellular carcinoma and the mechanism of traditional Chinese medicine[J]. Journal of hepatocellular carcinoma,2023, 10: 893-908.
16
SEMENZA G L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations[J]. The journal of clinical investigation, 2013, 123(9): 3664-3671.
17
李慧杰, 齐元富, 李秀荣. 缺氧诱导因子1在肿瘤进程中的作用机制研究[J]. 现代肿瘤医学, 2018, 26(18): 2979-2981.
18
WAN B, CHENG M, HE T, et al. UCHL5 promotes hepatocellular carcinoma progression by promoting glycolysis through activating Wnt/β-catenin pathway[J]. BioMed central cancer, 2024, 24(1): 618.
19
HU Y, XING Y, FAN G, et al. L-arginine combination with 5-fluorouracil inhibit hepatocellular carcinoma cells through suppressing iNOS/NO/AKT-mediated glycolysis[J]. Frontiers in pharmacology, 2024, 15:1391636.
20
LI Y, XU Q, YANG W, et al. Oleanolic acid reduces aerobic glycolysis-associated proliferation by inhibiting yes-associated protein in gastric cancer cells[J]. Gene, 2019, 712: 143956.
21
Yang Q, Lei X, He J, et al. N4-Acetylcytidine drives glycolysis addiction in gastric cancer via NAT10/SEPT9/HIF-1α positive feedback loop[J]. Advanced science, 2023, 10(23): e2300898.
22
郭德正, 周宗和, 罗兴成. HIF-1α与胃肠道肿瘤的关系研究进展[J].中国民康医学, 2015, 27(8): 83-85.
23
XU G, LI M, WU J, et al. Circular RNA circNRIP1 Sponges microRNA-138-5p to maintain hypoxia-induced resistance to 5-fluorouracil through HIF-1α-dependent glucose metabolism in gastric carcinoma[J]. Cancer management and research, 2020, 12:2789-2802.
24
赵林林. TCP1α在人胰腺导管腺癌中的表达及对胰腺癌细胞株生物学行为的影响[D]. 济南:山东大学, 2020.
25
CHEN M, CEN K, SONG Y, et al. NUSAP1-LDHA-glycolysis-lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma[J]. Cancer letters, 2023, 567: 216285.
26
SHANG J, XIA Q, SUN Y, et al. Bufalin-loaded multifunctional photothermal nanoparticles inhibit the anaerobic glycolysis by targeting SRC-3/HIF-1α pathway for improved mild photothermal therapy in CRC[J]. International journal of nanomedicine, 2024, 19: 7831-7850.
27
WANG J, WANG X, LIU Z, et al. IGFBP7 promotes gastric cancer by facilitating epithelial-mesenchymal transition of gastric cells[J].Heliyon, 2024, 10(10): e30986.
28
LIU M, YANG J, XU B, et al. Tumor metastasis: Mechanistic insights and therapeutic interventions[J]. MedComm, 2021, 2(4): 587-617.
29
MEI D, ZHU Y, ZHANG L, et al. The role of CTHRC1 in regulation of multiple signaling and tumor progression and metastasis[J].Mediators of inflammation, 2020, 2020: 9578701.
30
SEO J, JEONG D W, PARK J W, et al. Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells[J]. Communications biology, 2020, 3(1): 638.
31
DAI W, LI Y, SUN W, et al. Silencing of OGDHL promotes liver cancer metastasis by enhancing hypoxia inducible factor 1 α protein stability[J]. Cancer science, 2023, 114(4): 1309-1323.
32
王强, 郭德正, 刘焱伟, 等. HIF-1α及STAT3联合预测异时性结直肠癌肝转移[J]. 贵阳医学院学报, 2015, 40(7): 692-695.
33
XU L, HUAN L, GUO T, et al. LncRNA SNHG11 facilitates tumor metastasis by interacting with and stabilizing HIF-1α[J]. Oncogene,2020, 39(46): 7005-7018.
34
BIAN Y, YIN G, WANG G, et al. Degradation of HIF-1α induced by curcumol blocks glutaminolysis and inhibits epithelial-mesenchymal transition and invasion in colorectal cancer cells[J]. Cell biology and toxicology, 2023, 39(5): 1957-1978.
35
MU G, ZHU Y, DONG Z, et al. Calmodulin 2 facilitates angiogenesis and metastasis of gastric cancer via STAT3/HIF-1A/VEGF-A mediated macrophage polarization[J]. Frontiers in oncology, 2021, 11: 727306.
36
LEE PWT, KOSEKI LR, HAITANI T, et al. Hypoxia-inducible factordependent and independent mechanisms underlying chemoresistance of hypoxic cancer cells[J]. Cancers, 2024, 16(9): 1729.
37
WANG J, WANG X, LIU Z, et al. IGFBP7 promotes gastric cancer by facilitating epithelial-mesenchymal transition of gastric cells[J].Heliyon, 2024, 10(10): e30986.
38
IKEDA H, KAKEYA H. Targeting hypoxia-inducible factor 1 (HIF-1)signaling with natural products toward cancer chemotherapy[J]. The journal of antibiotics, 2021, 74(10): 687-695.
39
WAARTS M R, STONESTROM A J, PARK Y C, et al. Targeting mutations in cancer[J]. The journal of clinical investigation, 2022,132(8): e154943.
40
CUI C P, WONG C C, KAI A K, et al. SENP1 promotes hypoxiainduced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop[J]. Gut, 2017, 66(12): 2149-2159.
41
SUN W, LEI X, LU Q, et al. LncRNA FRMD6-AS1 promotes hepatocellular carcinoma cell migration and stemness by regulating SENP1/HIF-1α axis[J]. Pathology research and practice, 2023,243:154377.
42
CHEN J, LI L, FENG Y, et al. MKLN1-AS promotes pancreatic cancer progression as a crucial downstream mediator of HIF-1α through miR-185-5p/TEAD1 pathway[J]. Cell biology and toxicology, 2024, 40(1):30.
43
LEE S H, GOLINSKA M, GRIFFITHS J R. HIF-1-independent mechanisms regulating metabolic adaptation in hypoxic cancer cells[J]. Cells, 2021, 10(9): 2371.
[1] 辛岗, 刘佳妮, 胡崇珠, 杨颖. HER-2 表达与HER-2 阳性乳腺癌临床病理特征及靶向治疗疗效的关系[J/OL]. 中华乳腺病杂志(电子版), 2025, 19(01): 45-48.
[2] 赵海涛. 进展期胆管癌治疗探索及展望[J/OL]. 中华普通外科学文献(电子版), 2025, 19(02): 110-110.
[3] 虞先濬. 胰腺肿瘤外科:外科学遇见肿瘤学——拥抱精准、走向卓越[J/OL]. 中华普通外科学文献(电子版), 2025, 19(01): 27-27.
[4] 吴楚营, 叶凯. 不同部位胃肠道间质瘤的腹腔镜手术策略[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 224-227.
[5] 朱洪浩, 范新祥. 广东省医学会泌尿外科疑难病例多学科会诊(第18期)——女性尿道癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 120-124.
[6] 张亮, 高振, 宣婷婷, 王小博, 张磊, 印滇. 调强放疗联合驱动基因阳性晚期非小细胞肺癌靶向治疗的意义[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(01): 121-125.
[7] 陈用来, 谌莉, 李勇, 傅仕艳, 冉永红, 赵雅贞, 郝玉徽. 放射性肺纤维化的研究近展[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(06): 1042-1047.
[8] 陈博滔, 胡宽, 毛先海. 胆囊癌肿瘤微环境与系统治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 203-208.
[9] 吴春霖, 侯一夫, 陈凯, 赵冀, 唐世杰, 杨洪吉. 肝动脉灌注化疗联合PD-1/TKI 治疗不可切除性肝癌的安全性和疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 217-224.
[10] 黄忠晶, 张丽东, 伍子奕, 艾军华. 不可切除肝细胞癌的转化治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 41-45.
[11] 孙志鹏, 束斌, 王良, 黄鑫, 王鹏飞, 李广欣, 王小娟, 黎功, 杨世忠. 放疗联合靶向免疫新辅助治疗肝内胆管细胞癌的安全性与疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 92-96.
[12] 李伟男, 杨刚, 熊永福, 李强, 李敬东. 中晚期肝癌TACE 联合靶向免疫转化治疗后成功实施ALPPS 的初步经验[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 97-101.
[13] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[14] 沈小芳, 赵娜, 李克佳, 肖跃飞. 膜性肾病的靶抗原发现及靶向治疗研究进展[J/OL]. 中华肾病研究电子杂志, 2025, 14(01): 53-56.
[15] 宋然, 郑雅各. 仑伐替尼联合肝动脉插管化疗栓塞术治疗不可切除晚期肝癌的疗效及生存率影响因素分析[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(02): 120-124.
阅读次数
全文


摘要